As TNF‐α plays a central role in the regulation of inflammation, TNF‐blocking biologicals are already approved for the treatment of inflammatory diseases including rheumatoid arthritis, inflammatory bowel disease, and psoriasis 37, 38. This evidence concerns the gene TNF and psoriasis.